AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CRISPR Therapeutics AG Director's Dealing 2021

Jun 14, 2021

30936_dirs_2021-06-14_4308ab95-a910-43e4-ab86-757fc1bc5743.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2021-06-10

Reporting Person: Fleming Harold Edward (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-10	Stock Option (Right to Buy)	$123.71	A	25000	Acquired	2031-06-10	Common Shares (25000)	Direct

Footnotes

F1: This option was granted on June 10, 2021 with respect to 25,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments.